On July 23, 2025 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, reported its commitment to ongoing research to better understand the multiple effects of its novel spliceosome modulator, PH1, having demonstrated it may also act to inhibit key drivers in cancer tumors (Press release, Akari Therapeutics, JUL 23, 2025, View Source [SID1234654668]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to build on the scientific data already established for our novel PH1 spliceosome modulator payload with continued, ongoing research," commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. "In addition to the cytotoxic and immuno-oncology modes of action for this payload, we have also demonstrated its ability to induce cytotoxicity in cancer cells under the influence of key oncogenic drivers such as KRAS, BRAF, and FGFR3 (Patent WO2024220546A2). As such, we are continuing to further investigate how this novel payload may impact other key drivers relevant to cancer tumors, and we look forward to releasing this key data in the near future."
Akari’s ADCs utilize its novel spliceosome modulator payload, PH1, and have the potential to significantly improve future oncology therapies based on current preclinical data demonstrating the following:
• Killing cancer cells while activating the immune system: In addition to killing cancer cells, spliceosome modulation by the PH1 payload causes the accumulation of mis-spliced proteins, generating neoantigens that activate the immune system to further attack the cancer tumor.
• Reducing off-target toxicity: Linker is engineered to only release PH1 payload intracellularly within targeted cancer cells to mitigate off-target toxicity.
• Circumventing traditional cancer resistance mechanisms: PH1 is resistant to standard efflux transporters that can cause cancer cells to become resistant to current payloads used on ADCs.
Akari continues to build on this key data for its spliceosome modulator payload with further research ongoing on how the payload can also disrupt key drivers responsible for cancer cell growth. Preliminary data from additional preclinical research experiments testing activity of PH1 against an established oncogenic driver unique to a major tumor are expected before year-end.